PetVivo announces release of clinical study results on Spryng

PetVivo (PETV) announced that the Company has released the results of a clinical study conducted by Inotiv (NOTV), which examined the safety of intra-articular injections of a collagen-elastin hydrogel microparticulate biomaterial into the joints of dogs. “We were pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of this veterinary medical device when injected into the joints of dogs,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions that thereby enhances the lives of companion animals and their owners.” The data provided from the dogs enrolled in this study demonstrates the excellent safety profile of Spryng when injected IA into 40 joints across 20 individual dogs. Use of Spryng was similar to a benign control in regard to incidences of lameness, joint swelling, or pain after IA injection, and post-injection outcomes were most often no different than pre-injection baseline measures.